Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | TOP2A | P11388 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | DUT | P33316 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2489351 | 0.84 | KMT2A (0.42) | KMT2AHSD11B1MEN1MAPTMMP1 | |
| SCHEMBL2492931 | 0.84 | KMT2A (0.42) | KMT2AHSD11B1MEN1MAPTMMP1 | |
| SCHEMBL1508627 | 0.79 | KMT2A (0.48) | KMT2AHSD11B1MEN1MAPTBRD4 | |
| SCHEMBL22661899 | 0.79 | KMT2A (0.48) | KMT2AHSD11B1MEN1MAPTBRD4 | |
| SCHEMBL1508566 | 0.79 | KMT2A (0.48) | KMT2AHSD11B1MEN1MAPTBRD4 | |
| SCHEMBL2491074 | 0.77 | KMT2A (0.48) | KMT2AMEN1MAPT | |
| SCHEMBL1508950 | 0.74 | KMT2A (0.50) | KMT2AHSD11B1MEN1MAPTHTT | |
| SCHEMBL1508846 | 0.74 | KMT2A (0.50) | KMT2AHSD11B1MEN1MAPTHTT | |
| SCHEMBL22661866 | 0.74 | KMT2A (0.50) | KMT2AHSD11B1MEN1MAPTHTT | |
| SCHEMBL17685940 | 0.72 | THRB (0.38) | TOP2ATHRBDUTHSD11B1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172362-A1 | Imidazothiazole Derivatives Having Proline Ring Structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| US-20130172362-A1 | Imidazothiazole Derivatives Having Proline Ring Structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| US-20130172362-A1 | Imidazothiazole Derivatives Having Proline Ring Structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| US-8404691-B2 | Imidazothiazole derivatives having proline ring structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-03-26 | — | — | US | disclosed |
| US-8404691-B2 | Imidazothiazole derivatives having proline ring structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-03-26 | — | — | US | disclosed |
| EP-2380892-A1 | IMIDAZOTHIAZOLE DERIVATIVE HAVING PROLINE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2011-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172362-A1 | Imidazothiazole Derivatives Having Proline Ring Structure | MDM2, TP53, TP53BP1 | KMT2A 1912/4885TOP2A 656/4885THRB 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.